MarketCap
Facebook
X
Telegram
Poseida Therapeutics Operating Cycle | PSTX
Annual Operating Cycle Poseida Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51 | 12.7 | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 51 | 12.7 | 31.9 |
Quarterly Operating Cycle Poseida Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.3 | 43 | 34.1 | - | 100 | 46.4 | 77.3 | - | 15.2 | 3.92 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 100 | 3.92 | 42.2 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
223 | $ 3.59 | 1.85 % | $ 384 M |  USA |
 |
Jaguar Health
JAGX
|
964 | $ 0.48 | 10.08 % | $ 1.12 M | USA |
 |
Cerus Corporation
CERS
|
250 | $ 2.12 | 8.46 % | $ 404 M | USA |
 |
Pulmatrix
PULM
|
21.7 | $ 1.31 | -2.96 % | $ 4.78 B | USA |
 |
Fortress Biotech
FBIO
|
325 | $ 2.02 | 5.65 % | $ 56.4 M | USA |
 |
Inhibrx
INBX
|
24.6 | $ 90.76 | 0.17 % | $ 4.28 B | USA |
 |
Entera Bio Ltd.
ENTX
|
127 | $ 3.21 | -0.9 % | $ 148 M |  Israel |
 |
Flexion Therapeutics, Inc.
FLXN
|
40.6 | - | - | $ 459 M | USA |
 |
Inhibikase Therapeutics
IKT
|
6.48 | $ 1.64 | 5.48 % | $ 161 M | USA |
 |
Heron Therapeutics
HRTX
|
842 | $ 0.36 | -3.39 % | $ 60 M | USA |
 |
Aytu BioScience
AYTU
|
332 | $ 1.83 | 0.83 % | $ 22.5 M | USA |
 |
Innoviva
INVA
|
24.6 | $ 18.87 | -1.1 % | $ 1.27 B | USA |
 |
BioCardia
BCDA
|
198 | $ 0.94 | 0.9 % | $ 6.27 M | USA |
 |
Kindred Biosciences, Inc.
KIN
|
75.6 | - | 0.11 % | $ 419 M | USA |
 |
Shineco, Inc.
TYHT
|
137 | - | -3.90 % | $ 97.2 M |  China |
 |
Millendo Therapeutics, Inc.
MLND
|
111 | - | -5.36 % | $ 20.2 M | USA |
 |
Dyadic International
DYAI
|
78.4 | $ 0.38 | 3.5 % | $ 13.8 M | USA |
 |
Intec Pharma Ltd
NTEC
|
127 | - | -12.45 % | $ 17.7 M | Israel |
 |
Anika Therapeutics
ANIK
|
235 | $ 13.91 | 3.27 % | $ 199 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
383 | $ 74.57 | 1.66 % | $ 7.74 B | USA |
 |
Progenity, Inc.
PROG
|
879 | - | -3.47 % | $ 164 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
13.9 | - | 1.52 % | $ 136 M | USA |
 |
Seneca Biopharma, Inc.
SNCA
|
24.3 | - | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
733 | $ 58.33 | 2.1 % | $ 11.2 B | USA |
 |
Enanta Pharmaceuticals
ENTA
|
37.8 | $ 11.61 | 3.46 % | $ 248 K | USA |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
206 | $ 95.42 | 0.42 % | $ 7.08 B | USA |
 |
Lipocine
LPCN
|
3.76 M | $ 1.59 | -0.31 % | $ 8.66 M | USA |
 |
PTC Therapeutics
PTCT
|
646 | $ 64.91 | 1.2 % | $ 5.16 B | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
35.9 | $ 432.77 | 0.04 % | $ 9.71 B | USA |